Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

ASP Isotopes (ASPI) has filed a shelf registration for up to US$106.1 million of common stock, covering 23,160,682 shares.

See our latest analysis for ASP Isotopes.

ASP Isotopes' share price has been under pressure in the short term, with the stock down 42% over the past month and 31% year to date, while the 1 year total shareholder return is down 63%. However, the 3 year total shareholder return remains very large, which may reflect earlier optimism now being reassessed as the market weighs the risks and potential of the business.

If this kind of volatility has you looking further afield, it could be a good time to broaden your watchlist with nuclear energy infrastructure opportunities using the 90 nuclear energy infrastructure stocks

After such a sharp pullback, the key issue for ASP Isotopes now is whether most of the easy upside has already played out or if meaningful value still sits ahead, as the valuation section explains next.

Preferred Price-to-Sales Ratio of 18.1x: Is it justified?

ASP Isotopes last closed at $3.88, and based on the current P/S ratio of 18.1x, the stock is priced well above both peers and fair value estimates on this metric.

The price to sales ratio compares the company's market value to its revenue. For ASP Isotopes it is being used because the company is still loss making and traditional earnings based measures like P/E are not meaningful. With revenue of $26.93 million and a market cap of about $496.69 million, investors are paying a high multiple of current sales for exposure to its HALEU, specialist isotope and nuclear medical pipeline.

Relative to the estimated fair P/S ratio of 5.2x, the current 18.1x suggests the market is assigning a much richer valuation than this fair ratio implies. That gap could narrow over time if sentiment or expectations change. Compared against the US chemicals industry average P/S of 1.1x and a peer average of 1.5x, ASP Isotopes trades at a very steep premium, which underlines how differently the stock is being priced compared with more established producers.

Explore the SWS fair ratio for ASP Isotopes

Result: Price-to-Sales ratio of 18.1x (OVERVALUED)

However, ASP Isotopes still carries material risks, including its development stage status, an ongoing net loss of $193.11 million, and a P/S multiple far above sector and peer averages.

Find out about the key risks to this ASP Isotopes narrative.